A patient with high-risk HER2-negative early breast cancer has a germline PALB2 pathogenic variant but no BRCA1/2 mutation after accredited testing.

Question

A patient with high-risk HER2-negative early breast cancer has a germline PALB2 pathogenic variant but no BRCA1/2 mutation after accredited testing. Following neoadjuvant chemotherapy and surgery, which statement about adjuvant olaparib is correct in NHS practice?

Accepted Answer

PALB2 alone is outside NICE TA886 eligibility for adjuvant olaparib

Answer

Residual disease replaces the germline BRCA1/2 criterion in the appraisal

Answer

Any pathogenic homologous-recombination gene qualifies for two years of olaparib

Answer

HER2-negative status alone qualifies for olaparib when residual disease remains

Answer

PALB2 qualifies for one year of adjuvant olaparib on the same basis as BRCA2

Breast Cancer — SCE Medical Oncology MCQ

A patient with high-risk HER2-negative early breast cancer has a germline PALB2 pathogenic variant but no BRCA1/2 mutation after accredited testing. Following neoadjuvant chemotherapy and surgery, which statement about adjuvant olaparib is correct in NHS practice?